What the evidence says
The page has one source of treatment-outcome evidence on cannabidiol (CBD) in people at clinical high risk for psychosis (CHR-P). A 2026 review in Frontiers in Psychiatry (Oliver D) states that "a small clinical trial suggests that CBD can reduce symptom severity in people with CHR-P". The claim gives no effect size, no sample size and no trial methodology. The direction is therefore reported with medium confidence and the magnitude with low confidence. The sources do not name a mechanism.
The rest of the page comes from a 2026 cross-sectional survey of CHR-P individuals (Oliver D). It measures attitudes, not outcomes. In that survey, 76% were willing to consider taking CBD. Among those willing, 62% were willing to take it for two years or more. These are statements of willingness, and the claims note they may not match actual adherence over time.
Participants also held clear expectations. 74% thought their symptoms would improve with CBD, and 2% thought it would make them worse. On side effects, 73% thought CBD would be more tolerable than their current medications, and 8% thought it would be worse. These are beliefs, not measured outcomes. They say nothing about whether CBD improves symptoms or is better tolerated.
When participants ranked options, CBD had a median rank of 3. Antipsychotics were the least popular, with a median rank of 5 (p<0.001). The claims note this rests on rankings from 28 participants.
Several outcomes people would expect to see are absent. The sources give no trial effect size, no adverse-event data, no adherence data, and no data on transition to psychosis. Measured outcomes come only from the one small trial described secondhand. Everything else is stated preference.